We want to share a quick update and applaud one of our 50-State Network advocates Danielle Yevsa who spoke up about Fail First/ Step Therapy practices in the New York Daily News.

Patients, advocates and health care providers came together on the steps of the state capitol in Albany, NY, August 3rd, to call on Governor Andrew Cuomo to sign into law legislation aimed at ensuring that patients and their doctors have the final say in their medication treatment plans. During this past legislative session, both the […]

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

Imagine you’ve been living with rheumatoid arthritis for more than ten years.

At its core, HB 1366 boils down to two words: Trust and transparency.

HB 505 takes positive steps toward updating Ohio law to cover biologics and biosimilars in a
way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique,
complex structures made from living cells that are not easily replicated. A small change or
difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.